{"id":"https://openalex.org/W1595109869","doi":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI\u20100052 (marizomib) in a human plasmacytoma xenograft murine model","display_name":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI\u20100052 (marizomib) in a human plasmacytoma xenograft murine model","publication_year":2010,"publication_date":"2010-03-12","ids":{"openalex":"https://openalex.org/W1595109869","doi":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","mag":"1595109869","pmid":"https://pubmed.ncbi.nlm.nih.gov/20331453","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4427841"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2141.2010.08144.x","doi":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08144.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08144.x","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102256659","display_name":"Ajita Singh","orcid":"https://orcid.org/0000-0002-6070-4232","observed_orcids":["https://orcid.org/0000-0002-6070-4232"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajita V. Singh","raw_affiliation_strings":["The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000260833","display_name":"Michael A. Palladino","orcid":"https://orcid.org/0000-0002-4687-7612","observed_orcids":["https://orcid.org/0000-0002-4687-7612"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael A. Palladino","raw_affiliation_strings":["Nereus Pharmaceuticals, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111762498","display_name":"Kenneth G. Lloyd","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George Kenneth Lloyd","raw_affiliation_strings":["Nereus Pharmaceuticals, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083370321","display_name":"Barbara C. M. Potts","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Barbara C. Potts","raw_affiliation_strings":["Nereus Pharmaceuticals, San Diego, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nereus Pharmaceuticals, San Diego, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":["Contributed equally as senior authors","The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Contributed equally as senior authors","institution_ids":[]},{"raw_affiliation_string":"The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Contributed equally as senior authors","The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Contributed equally as senior authors","institution_ids":[]},{"raw_affiliation_string":"The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5006765393","https://openalex.org/A5032464400"],"corresponding_institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":6.4091,"has_fulltext":true,"cited_by_count":63,"citation_normalized_percentile":{"value":0.96920914,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":90,"max":99},"biblio":{"volume":"149","issue":"4","first_page":"550","last_page":"559"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9707000255584717,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9707000255584717,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.024800000712275505,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/marizomib","display_name":"marizomib","score":0.9549999833106995},{"id":"https://openalex.org/keywords/npi-0052","display_name":"NPI-0052","score":0.9940000176429749},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.878000020980835},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/plasmacytoma","display_name":"plasmacytoma","score":0.8769999742507935},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7699999809265137},{"id":"https://openalex.org/keywords/proteasome-inhibition","display_name":"proteasome inhibition","score":0.722000002861023},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.6290000081062317},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.675000011920929},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5870000123977661},{"id":"https://openalex.org/keywords/bortezomib-resistance","display_name":"bortezomib resistance","score":0.8429999947547913},{"id":"https://openalex.org/keywords/mm-1s-cells","display_name":"MM.1S cells","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C2778964538","wikidata":"https://www.wikidata.org/wiki/Q2090167","display_name":"Plasmacytoma","level":3,"score":0.7763868570327759},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.700012743473053},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.6896376013755798},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.601820707321167},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4979696273803711},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4838044047355652},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45938852429389954},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.44733956456184387},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.3756653070449829},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3722774386405945},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32273566722869873},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11923345923423767}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007668","descriptor_name":"Kidney","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010954","descriptor_name":"Plasmacytoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010954","descriptor_name":"Plasmacytoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010954","descriptor_name":"Plasmacytoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061988","descriptor_name":"Proteasome Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/j.1365-2141.2010.08144.x","doi":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08144.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:20331453","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20331453","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Journal Article"},{"id":"pmh:oai:europepmc.org:3388823","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4427841","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4427841","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4427841","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Br J Haematol","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1111/j.1365-2141.2010.08144.x","doi":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2010.08144.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2010.08144.x","source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3006657251","display_name":null,"funder_award_id":"P50100707","funder_id":"https://openalex.org/F4320332505","funder_display_name":"U.S. Public Health Service"},{"id":"https://openalex.org/G3549977710","display_name":"Host-tumor cell interaction in myeloma: therapeutic applications","funder_award_id":"5p01ca078378-15","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G4680808690","display_name":null,"funder_award_id":"P01-CA078378","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G4933731489","display_name":"SPORE in Multiple Myeloma","funder_award_id":"P50CA100707","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G5276536440","display_name":"Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications","funder_award_id":"R01CA050947","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G669258595","display_name":null,"funder_award_id":"P50-100707","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000001880","display_name":null,"funder_award_id":"PO1-CA078378","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G9000867162","display_name":"Integrative Oncogenomics of Multiple Myeloma","funder_award_id":"P01CA155258","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1595109869.pdf","grobid_xml":"https://content.openalex.org/works/W1595109869.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1518640128","https://openalex.org/W1573531091","https://openalex.org/W1589662393","https://openalex.org/W1607209090","https://openalex.org/W1646203193","https://openalex.org/W1935443268","https://openalex.org/W1968229731","https://openalex.org/W1980471295","https://openalex.org/W1987583882","https://openalex.org/W1991915276","https://openalex.org/W2000246028","https://openalex.org/W2010184965","https://openalex.org/W2021242983","https://openalex.org/W2023687151","https://openalex.org/W2026642838","https://openalex.org/W2034941135","https://openalex.org/W2063533508","https://openalex.org/W2067653691","https://openalex.org/W2091823485","https://openalex.org/W2096207943","https://openalex.org/W2108235071","https://openalex.org/W2118820477","https://openalex.org/W2120590293","https://openalex.org/W2124560610","https://openalex.org/W2129752729","https://openalex.org/W2132485651","https://openalex.org/W2138077682","https://openalex.org/W2138102966","https://openalex.org/W2140182533","https://openalex.org/W2145412346","https://openalex.org/W2147576659","https://openalex.org/W2171513236","https://openalex.org/W2993774309"],"related_works":["https://openalex.org/W2550365187","https://openalex.org/W2131491521","https://openalex.org/W1568773552","https://openalex.org/W3159718164","https://openalex.org/W7098059288","https://openalex.org/W2993774309","https://openalex.org/W2551142268","https://openalex.org/W2243792761","https://openalex.org/W2244830292","https://openalex.org/W2244485162"],"abstract_inverted_index":{"Our":[0,78],"previous":[1],"study":[2],"showed":[3,80,177],"that":[4,35,81,157],"the":[5,50,86,160,167],"novel":[6],"proteasome":[7,100,135,191],"inhibitor":[8],"NPI-0052":[9,36,59,71,158,176],"induces":[10],"apoptosis":[11],"in":[12,60,89,112,137,142,154,193],"multiple":[13],"myeloma":[14],"(MM)":[15],"cells":[16],"resistant":[17],"to":[18],"conventional":[19],"and":[20,42,107,122,127,139,163,195],"bortezomib":[21],"(Velcade,":[22],"Takeda,":[23],"Boston,":[24],"MA,":[25],"USA)":[26],"therapies.":[27],"In":[28],"vivo":[29],"studies":[30,48,69],"using":[31,72],"human":[32,73],"MM-xenografts":[33],"demonstrated":[34,156],"is":[37],"well":[38],"tolerated,":[39],"prolongs":[40],"survival,":[41],"reduces":[43],"tumour":[44,179],"recurrence.":[45],"These":[46],"preclinical":[47],"provided":[49],"basis":[51],"for":[52],"an":[53,90],"ongoing":[54],"phase-1":[55],"clinical":[56],"trial":[57],"of":[58,70,150,172,190],"relapsed/refractory":[61],"MM":[62,74],"patients.":[63],"Here":[64],"we":[65],"performed":[66],"pharmacodynamic":[67],"(PD)":[68],"xenograft":[75],"murine":[76],"model.":[77],"results":[79],"NPI-0052:":[82],"(i)":[83],"rapidly":[84],"left":[85,159],"vascular":[87,161],"compartment":[88],"active":[91],"form":[92],"after":[93],"intravenous":[94],"(i.v.)":[95],"administration,":[96],"(ii)":[97],"inhibited":[98],"20S":[99],"chymotrypsin-like":[101],"(CT-L,":[102],"beta5),":[103],"trypsin-like":[104],"(T-L,":[105],"beta2),":[106],"caspase-like":[108],"(C-L,":[109],"beta1)":[110],"activities":[111],"extra-vascular":[113],"tumours,":[114],"packed":[115],"whole":[116],"blood":[117],"(PWB),":[118],"lung,":[119],"liver,":[120],"spleen,":[121],"kidney,":[123],"but":[124,197],"not":[125,198],"brain":[126],"(iii)":[128],"triggered":[129],"a":[130],"more":[131],"sustained":[132],"(>24":[133],"h)":[134],"inhibition":[136,189],"tumours":[138,194],"PWB":[140,196],"than":[141],"other":[143],"organs":[144,165],"(<24":[145],"h).":[146],"Tissue":[147],"distribution":[148],"analysis":[149],"radiolabeled":[151],"compound":[152],"(3H-NPI-0052)":[153],"mice":[155,174],"space":[162],"entered":[164],"as":[166],"parent":[168],"compound.":[169],"Importantly,":[170],"treatment":[171],"MM.1S-bearing":[173],"with":[175,187],"reduced":[178],"growth":[180],"without":[181],"significant":[182],"toxicity,":[183],"which":[184],"was":[185],"associated":[186],"prolonged":[188],"activity":[192],"normal":[199],"tissues.":[200]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}